Effect of S-1 on serum TK1, VEGF, IGF-1 and tumor biomarkers, estrgen levels in patients with advanced breast cancer
- VernacularTitle:替吉奥对晚期乳腺癌患者血清TK1、VEGF、IGF－1和肿瘤标志物、雌激素水平的影响
- Author:
Jianlin ZHOU
;
Wufang ZHANG
;
Wusen YANG
;
Xingwu WANG
;
Fen LI
- Publication Type:Journal Article
- Keywords:
S-1;
advanced breast cancer;
thymidine kinase-1;
vascular endothelial growth factor;
insulin-like growth factor-1;
tumor biomarkers;
estrgen
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(8):69-71
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of S-1 on serum thymidine kinase-1 ( TK1 ) , vascular endothelial growth factor ( VEGF ) and insulin-like growth factor-1 (IGF-1) and tumor biomarkers, estrgen levels and quality of life in patients with advanced breast cancer.Methods 69 cases with advanced breast cancer from January 2014 to May 2015 in the hospital were selected and randomly divided into two groups.34 cases in control group were treated by conventional therapy, and 34 cases in experimental group were treated with S-1.Serum TK1, VEGF and IGF-1, tumor biomarkers, estrogen level and quality of life score were compared pre-and post-treatment.ResuIts Compared with control group, the levels of VEGF, IGF-1 and TK1 were lower (P<0.05), serum CA125, CEA and CA15-3 concentrations were lower (P<0.05),the LH, E2 and E1 levels were lower (P<0.05) and the survival quality score was higher in experimental group ( P<0.05 ) .ConcIusion S-1 has better clinical curative effect in treatment of patients with advanced breast cancer, and effectively reduce serum TK1, VEGF, IGF-1, tumor biomarker levels, improve the quality of survival, which has important significance.
